Transformative Weight Loss & Fertility Enhancements with Monjaro – ARC Summit
Dr. Awad has outlined the significant risks associated with obesity, including type 2 diabetes, hypertension, heart disease, dyslipidemia, stroke, and osteoarthritis. These conditions are particularly pertinent for patients seeking fertility treatments, as they can complicate both the process and the pregnancy itself. In our clinic, we’ve observed that obesity can lead to decreased ovarian function, a reduced response to fertility medications, and an increased need for gonadotropins, which may contribute to higher miscarriage rates and lower live birth rates from IVF procedures. Moreover, maternal and fetal complications during pregnancy are heightened in obese patients.
To address these issues, our clinic has implemented strategies to improve patient outcomes, especially for those with PCOS who are often insulin-resistant. A significant number of our PCOS patients, ranging from 50 to 70%, exhibit insulin resistance, and many are also obese. Traditionally, treatments like Metformin have been used to manage insulin resistance, aiding in ovulation but not significantly affecting weight loss. Recently, we’ve started using the drug Monjaro (Tirzepatide), which has shown promising results in not only improving insulin sensitivity but also facilitating substantial weight loss—an average of 32 pounds, with some patients losing up to 58 pounds.
Monjaro is administered via injection, starting at a low dosage of 2.5 milligrams per week and potentially increasing based on the patient’s response and treatment needs. It’s crucial that patients using weight loss medications like Monjaro use birth control to avoid pregnancy due to unknown potential effects on the fetus. Our clinic closely monitors patients on this medication, requiring regular checks of TSH, lipids, hemoglobin A1c, and a comprehensive metabolic panel.
For patients undergoing IVF, we aim to reduce their BMI to below 40 before starting treatments, as higher BMIs significantly increase procedural risks and complications. Our approach is holistic, focusing not only on immediate fertility outcomes but also on long-term health and safety. The integration of advanced genetic screening, including for BRCA mutations associated with an increased risk of ovarian cancer, further exemplifies our commitment to personalized and precautious care.
This proactive approach in managing weight and health issues reflects our commitment to enhancing fertility outcomes while ensuring the safety and well-being of our patients. We continuously strive to adapt and implement the most effective treatments and procedures to assist our patients in achieving their family-building goals safely and successfully.
